8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
May 13, 2026·SEC
Material company update
Apr 1, 2026·SEC
Alto Neuroscience, Inc.(ANRO)Earnings, Financials & Key Ratios
ANRO•NYSE
Price updated Jun 11, 2026
AboutAlto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company that engages in the psychiatry drug development business. The company develops ALTO-100 for the treatment of patients with major depressive disorder (MDD) and post-traumatic stress disorder; ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties to treat patients with MDD; and ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor for the treatment of cognitive impairment associated with schizophrenia. It also develops ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist to treat patients with MDD and higher levels of anhedonia, and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor for the treatment of MDD. In addition, the company develops novel pharmacodynamically synergistic combinations and an AI-enabled biomarker platform that combine sources of information on patients brain activity and behavior to identify patients to respond to novel product candidates. Alto Neuroscience, Inc. was incorporated in 2019 and is based in Los Altos, California.Show more
- Revenue$0
- EBITDA-$66M+11.7%
- Net Income-$63M-2.9%
- EPS (Diluted)-2.19+12.4%
- ROE-41.8%+72.9%
- Debt/Equity0.03-73.9%
- Interest Coverage-26.88+41.2%
ANRO Key Insights
Alto Neuroscience, Inc. (ANRO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 94 (top 6%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 17.3% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ANRO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANRO Price & Volume
Alto Neuroscience, Inc. (ANRO) stock price & volume — 10-year historical chart
Loading chart...
ANRO Growth Metrics
Alto Neuroscience, Inc. (ANRO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-17.6%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-6.44%
Return on Capital
10 Years-55.89%
5 Years-55.89%
3 Years-51.34%
Last Year-38.93%
ANRO Recent Earnings
Alto Neuroscience, Inc. (ANRO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (60%)
Q2 2026Latest
May 13, 2026EPS
$0.80
Est $0.56
-42.9%
Revenue
—
Q2 2026
Mar 16, 2026EPS
$0.45
Est $0.56
+19.6%
Revenue
—
Q4 2025
Nov 12, 2025EPS
$0.52
Est $0.66
+21.2%
Revenue
—
Q3 2025
Aug 13, 2025EPS
$0.65
Est $0.57
-14.0%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.80vs $0.56-42.9% | — |
| Q2 2026 | Mar 16, 2026 | $0.45vs $0.56+19.6% | — |
| Q4 2025 | Nov 12, 2025 | $0.52vs $0.66+21.2% | — |
| Q3 2025 | Aug 13, 2025 | $0.65vs $0.57-14.0% | — |
Based on last 12 quarters of dataView full earnings history →
ANRO Peer Comparison
Alto Neuroscience, Inc. (ANRO) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SAVA | 63.77M | 1.32 | -2.54 | -95.77% | ||||
 NRXP | 67.76M | 3.92 | -2.93 | -10.7% | ||||
 INVA | 1.66B | 22.44 | 6.80 | 18.52% | 118.91% | 47.59% | 0.23 | |
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 AXSM | 13.06B | 253.77 | -68.96 | 65.55% | -26.59% | -260.01% | 2.73 | |
 INTR | 2.52B | 5.71 | 10.17 | 50.54% | 8.99% | 14.24% | 2.85 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 ILMN | 25.25B | 166.21 | 30.50 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare ANRO vs Peers
Alto Neuroscience, Inc. (ANRO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANRO Income Statement
Alto Neuroscience, Inc. (ANRO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Sales/Revenue | 210K | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | -100% | - | - | - | - |
Cost of Goods Sold | 145K | 342K | 0 | 502K | 661K | 284K |
COGS % of Revenue | 69.05% | - | - | - | - | - |
Gross Profit | 65K▲ 0% | -342K▼ 626.2% | 0▲ 100.0% | -502K▲ 0% | -661K▼ 31.7% | -284K▲ 0% |
Gross Margin % | 30.95% | - | - | - | - | - |
Gross Profit Growth % | - | -626.15% | 100% | - | -31.67% | - |
Operating Expenses | 12.12M | 28.85M | 37.81M | 68.11M | 65.7M | -55.19M |
OpEx % of Revenue | 5771.9% | - | - | - | - | - |
Selling, General & Admin | 3.75M | 5.16M | 7.52M | 21.61M | 20.75M | 21.89M |
SG&A % of Revenue | 1786.19% | - | - | - | - | - |
Research & Development | 8.37M | 23.69M | 30.29M | 47M | 45.62M | 55.94M |
R&D % of Revenue | 3985.71% | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | -502K | -661K | -1.28M |
Operating Income | -12.06M▲ 0% | -29.19M▼ 142.1% | -37.81M▼ 29.5% | -68.61M▼ 81.5% | -66.36M▲ 3.3% | 54.9M▲ 0% |
Operating Margin % | -5740.95% | - | - | - | - | - |
Operating Income Growth % | - | -142.14% | -29.52% | -81.46% | 3.27% | - |
EBITDA | -11.91M | -28.85M | -37.44M | -74.41M | -65.7M | 55.51M |
EBITDA Margin % | -5671.9% | - | - | - | - | - |
EBITDA Growth % | - | -142.21% | -29.76% | -98.78% | 11.71% | 180.07% |
D&A (Non-Cash Add-back) | 145K | 342K | 373K | -5.8M | 661K | 605K |
EBIT | -9.19M | -27.71M | -34.94M | -62.81M | -66.36M | -73.34M |
Net Interest Income | 2K | 114K | 979K | 10.23M | 4.13M | 3.92M |
Interest Income | 2K | 114K | 2.35M | 8.85M | 6.6M | 6.34M |
Interest Expense | 0 | 0 | 1.37M | -1.38M | 2.47M | 2.42M |
Other Income/Expense | 2.87M | 1.48M | 1.5M | 7.18M | 3.13M | -129.21M |
Pretax Income | -9.19M▲ 0% | -27.71M▼ 201.6% | -36.3M▼ 31.0% | -61.43M▼ 69.2% | -63.24M▼ 2.9% | -74.31M▲ 0% |
Pretax Margin % | -4374.76% | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -9.19M▲ 0% | -27.71M▼ 201.6% | -36.3M▼ 31.0% | -61.43M▼ 69.2% | -63.24M▼ 2.9% | -74.31M▲ 0% |
Net Margin % | -4374.76% | - | - | - | - | - |
Net Income Growth % | - | -201.62% | -31.02% | -69.21% | -2.94% | -17.6% |
Net Income (Continuing) | -9.19M | -27.71M | -36.3M | -61.43M | -63.24M | -74.31M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.36▲ 0% | -1.08▼ 200.0% | -1.35▼ 25.0% | -2.50▼ 85.2% | -2.19▲ 12.4% | -2.26▲ 0% |
EPS Growth % | - | -200% | -25% | -85.19% | 12.4% | -6.44% |
EPS (Basic) | -0.36 | -1.08 | -1.35 | -2.50 | -2.19 | - |
Diluted Shares Outstanding | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M | 32.89M |
Basic Shares Outstanding | 25.57M | 25.57M | 26.88M | 24.6M | 28.85M | 32.89M |
Dividend Payout Ratio | - | - | - | - | - | - |
ANRO Balance Sheet
Alto Neuroscience, Inc. (ANRO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Total Current Assets | 27.68M | 49.22M | 85.39M | 169.34M | 177.72M | 269.13M |
Cash & Short-Term Investments | 25.7M | 48.34M | 82.55M | 168.23M | 176.48M | 263.76M |
Cash Only | 25.7M | 48.34M | 82.55M | 168.23M | 176.48M | 263.76M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.74M | 546K | 8K | 0 | 0 | 0 |
Days Sales Outstanding | 3.03K | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 2.31M | 30K | 1.23M | 5.36M |
Total Non-Current Assets | 1.11M | 1.63M | 1.24M | 8.21M | 6.97M | 7.13M |
Property, Plant & Equipment | 1.06M | 1.58M | 1.11M | 7.7M | 6.13M | 6.29M |
Fixed Asset Turnover | 0.20x | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 500K | 500K | 1M |
Other Non-Current Assets | 50K | 55K | 131K | 4K | 338K | 838K |
Total Assets | 28.79M▲ 0% | 50.85M▲ 76.6% | 86.63M▲ 70.3% | 177.54M▲ 104.9% | 184.69M▲ 4.0% | 276.26M▲ 0% |
Asset Turnover | 0.01x | - | - | - | - | 0.00x |
Asset Growth % | - | 76.61% | 70.35% | 104.95% | 4.03% | 21.44% |
Total Current Liabilities | 1.81M | 5.56M | 5.61M | 10.01M | 11.32M | 13.12M |
Accounts Payable | 600K | 1.61M | 1.07M | 1.58M | 1.88M | 3.37M |
Days Payables Outstanding | 1.51K | 1.71K | - | 1.15K | 1.04K | 2.88K |
Short-Term Debt | 0 | 283K | 0 | 0 | 585K | 2.14M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.19M | 3.54M | 0 | 0 | 8.86M | 7.61M |
Current Ratio | 15.30x | 8.85x | 15.22x | 16.92x | 15.69x | 20.52x |
Quick Ratio | 15.30x | 8.85x | 15.22x | 16.92x | 15.69x | 20.52x |
Cash Conversion Cycle | - | - | - | - | - | - |
Total Non-Current Liabilities | 39.46M | 83.7M | 152.69M | 16.07M | 22.22M | 19.77M |
Long-Term Debt | 38.16M | 81.7M | 9.86M | 11.56M | 3.82M | 3.56M |
Capital Lease Obligations | 0 | 123K | 0 | 4.52M | 0 | 12M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1.3M | 1.88M | 142.83M | 0 | 18.4M | 16.22M |
Total Liabilities | 41.27M | 89.26M | 158.3M | 26.08M | 33.55M | 32.89M |
Total Debt | 38.16M | 82.11M | 9.99M | 16.94M | 4.41M | 5.69M |
Net Debt | 12.46M | 33.76M | -72.56M | -151.28M | -172.08M | -258.07M |
Debt / Equity | - | - | - | 0.11x | 0.03x | 0.02x |
Debt / EBITDA | - | - | - | - | - | 0.10x |
Net Debt / EBITDA | - | - | - | - | - | -4.65x |
Interest Coverage | - | - | -25.50x | -45.68x | -26.88x | -30.35x |
Total Equity | -12.48M▲ 0% | -38.41M▼ 207.8% | -71.67M▼ 86.6% | 151.46M▲ 311.3% | 151.14M▼ 0.2% | 243.37M▲ 0% |
Equity Growth % | - | -207.79% | -86.62% | 311.32% | -0.21% | 10.99% |
Book Value per Share | -0.49 | -1.50 | -2.67 | 6.16 | 5.24 | 7.40 |
Total Shareholders' Equity | -12.48M | -38.41M | -71.67M | 151.46M | 151.14M | 243.37M |
Common Stock | 1K | 1K | 0 | 3K | 3K | 3K |
Retained Earnings | -12.95M | -40.66M | -76.97M | -138.4M | -201.63M | -227.87M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -22K | -46K | -79K | -101K | 22K | 13K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
ANRO Cash Flow Statement
Alto Neuroscience, Inc. (ANRO) cash flow — operating, investing & free cash flow history
| Metric | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|
Cash from Operations | -9.26M | -20.39M | -33.45M | -47.42M | -51.77M | -62.3M |
Operating CF Margin % | -4410.48% | - | - | - | - | - |
Operating CF Growth % | - | -120.19% | -64.01% | -41.78% | -9.16% | -54.49% |
Net Income | -9.19M | -27.71M | -36.3M | -61.43M | -63.24M | -74.31M |
Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K | 674K |
Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M | 8.11M | 4.19M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 125K | 632K | 291K | 1.81M | 2.67M | 6.83M |
Working Capital Changes | -572K | 4.58M | -698K | 4.06M | 33K | 299K |
Change in Receivables | -1.28M | 1.16M | 325K | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 458K | 1.01M | -632K | 516K | 221K | 1.98M |
Cash from Investing | -680K | -732K | -470K | -2.08M | -24K | -556K |
Capital Expenditures | -680K | -732K | -470K | -2.08M | -24K | -556K |
CapEx % of Revenue | 323.81% | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 31.69M | 43.79M | 68.13M | 135.69M | 60.08M | 165.89M |
Debt Issued (Net) | 0 | 9.82M | 0 | 1.25M | 10.1M | 750K |
Equity Issued (Net) | 31.89M | 34.3M | 70M | 137.58M | 49.98M | 164.91M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | -167K | -167K |
Other Financing | -205K | -341K | -1.87M | -3.14M | 0 | 229K |
Net Change in Cash | 21.7M▲ 0% | 22.64M▲ 4.3% | 34.2M▲ 51.1% | 86.18M▲ 152.0% | 8.26M▼ 90.4% | 103.01M▲ 0% |
Free Cash Flow | -9.94M▲ 0% | -21.13M▼ 112.5% | -33.92M▼ 60.6% | -49.5M▼ 45.9% | -51.79M▼ 4.6% | -62.86M▲ 0% |
FCF Margin % | -4734.29% | - | - | - | - | - |
FCF Growth % | - | -112.49% | -60.55% | -45.94% | -4.63% | -14.56% |
FCF per Share | -0.39 | -0.83 | -1.26 | -2.01 | -1.80 | -1.91 |
FCF Conversion (FCF/Net Income) | 1.01x | 0.74x | 0.92x | 0.77x | 0.82x | 0.85x |
Interest Paid | 0 | 0 | 912K | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
ANRO Key Ratios
Alto Neuroscience, Inc. (ANRO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -153.99% | -41.8% | -47.22% |
| Return on Invested Capital (ROIC) | - | - | - | - | -1409.31% |
| Debt / Equity | - | - | 0.11x | 0.03x | 0.02x |
| Interest Coverage | - | -25.50x | -45.68x | -26.88x | -30.35x |
| FCF Conversion | 0.74x | 0.92x | 0.77x | 0.82x | 0.85x |
| Revenue Growth | -100% | - | - | - | - |
Related:ANRO Dividend History·ANRO Revenue History·ANRO Price History·ANRO P/E History·ANRO Financial Ratios·ANRO Institutional Holders
ANRO SEC Filings & Documents
Alto Neuroscience, Inc. (ANRO) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANRO Frequently Asked Questions
Alto Neuroscience, Inc. (ANRO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Alto Neuroscience, Inc. (ANRO) grew revenue by 0.0% over the past year. Growth has been modest.
Alto Neuroscience, Inc. (ANRO) reported a net loss of $74.3M for fiscal year 2025.
Dividend & Returns
Alto Neuroscience, Inc. (ANRO) has a return on equity (ROE) of -41.8%. Negative ROE indicates the company is unprofitable.
Alto Neuroscience, Inc. (ANRO) had negative free cash flow of $62.9M in fiscal year 2025, likely due to heavy capital investments.